IRadimed Lifts 2025 Outlook After Record Q2

iRadimed Corporation reported a record $20.4 million in Q2 2025 revenue, marking its sixteenth consecutive quarter of record growth and a 14% year-over-year increase. GAAP diluted EPS rose 18% to $0.45, and the company raised its full-year 2025 revenue guidance to $80.0-$82.5 million and GAAP EPS guidance to $1.60-$1.70. For Q3 2025, iRadimed expects revenue of $20.5-$20.9 million and adjusted EPS of $0.45-$0.49, both above prior estimates. The company maintains a strong gross margin of 78%, credits manufacturing efficiency, and anticipates some temporary operational inefficiencies with its facility move in July. Future growth is expected from the upcoming commercialization of its next-generation MRI-compatible IV infusion pump, set to begin late 2025. Although iRadimed's share price has risen 6.1% year-to-date, it has lagged the S&P 500, but management sees positive earnings momentum supporting stockholder value.